| Autor: |
Lemieux P; Angiotech Pharmaceuticals, Inc., Vancouver, British Columbia, Canada., Harvey J, Guise T, Dallas M, Oesterreich S, Yin Jj, Selander K, Fuqua S |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 1999 Sep; Vol. 14 (9), pp. 1570-5. |
| DOI: |
10.1359/jbmr.1999.14.9.1570 |
| Abstrakt: |
The mechanisms controlling the formation of osteolytic bone metastases in patients with breast cancer are still poorly understood. To explore the role of motility in the establishment of osteolytic bone metastases, we have used a model of bone metastasis in which MDA-MB-231 breast cancer cells exhibiting low (hsp27-transfectants) and high (control-transfectant) endogenous cell motility were compared. We found that MDA-MB-231 cells exhibiting low cell motility were less capable of establishing osteolytic lesions. The number and the area of the osteolytic lesions in mice inoculated with low motility cells were both significantly smaller. Histomorphometry of bone lesions also demonstrated less tumor area in mice bearing hsp27 transfectants although there was no difference in the osteoclast number per square millimeter of tumor-bone interface. These data suggest that cell motility may be an important mechanism in the metastatic cascade of breast cancer cells to the bone and that controlling cell motility may be a useful target to prevent the establishment of osteolytic bone metastases. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text